Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor ty- rosine kinase signaling - Wilhelm, SM; Adnane, L; Newell, P (Mol Cancer Ther, 2008)
et al.